The category of EAF1 Activators comprises a range of chemical compounds that, while not directly activating EAF1, can potentially influence its activity indirectly through their effects on chromatin remodeling and transcriptional regulation. EAF1, being involved in transcriptional processes and potentially in chromatin organization, can be modulated by changes in the chromatin landscape and transcriptional dynamics within the cell.
The first group of these compounds includes histone deacetylase inhibitors such as Trichostatin A, SAHA (Vorinostat), Valproic Acid, Romidepsin, Mocetinostat, Panobinostat, and Nicotinamide. These inhibitors alter the acetylation status of histones, leading to changes in chromatin structure, which can subsequently influence the transcriptional regulatory functions of EAF1. For instance, Trichostatin A and Vorinostat, by increasing histone acetylation, can lead to a more open chromatin state, potentially enhancing the accessibility of transcription factors and co-regulatory proteins like EAF1 to their target genes. Another significant group comprises compounds that affect DNA methylation and histone methylation, including 5-Azacytidine, RG108, and BIX-01294. These chemicals can alter the epigenetic marks on DNA and histones, thereby potentially influencing the activity of EAF1 in the context of transcriptional regulation and chromatin organization. Additionally, compounds like Caffeine and Curcumin, known to affect multiple signaling pathways, can indirectly modulate transcriptional processes and chromatin dynamics, potentially impacting the functional role of EAF1.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
A histone deacetylase inhibitor that can modulate chromatin structure, potentially affecting EAF1 function. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor, can alter DNA methylation, potentially influencing EAF1 activity. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Another histone deacetylase inhibitor, potentially affecting EAF1 through chromatin remodeling. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $85.00 | 9 | |
A histone deacetylase inhibitor, can influence gene expression and chromatin structure, potentially impacting EAF1. | ||||||
Histone Lysine Methyltransferase Inhibitor Inhibitor | 935693-62-2 free base | sc-202651 | 5 mg | $148.00 | 4 | |
An inhibitor of G9a histone methyltransferase, can affect histone methylation, potentially influencing EAF1. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $128.00 $505.00 | 2 | |
A DNA methyltransferase inhibitor, potentially impacting EAF1 by altering DNA methylation patterns. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $214.00 $622.00 | 1 | |
A histone deacetylase inhibitor, can modulate chromatin structure, potentially affecting EAF1 activity. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $210.00 $242.00 $1434.00 | 2 | |
A histone deacetylase inhibitor, potentially influencing EAF1 through alterations in chromatin structure. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $196.00 | 9 | |
A potent histone deacetylase inhibitor, potentially impacting EAF1 function. | ||||||
Nicotinamide | 98-92-0 | sc-208096 sc-208096A sc-208096B sc-208096C | 100 g 250 g 1 kg 5 kg | $43.00 $65.00 $200.00 $815.00 | 6 | |
A form of vitamin B3 and a histone deacetylase inhibitor, potentially affecting EAF1. | ||||||